tbuckley/cabot-search huggingface dataset:
The impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The M. D. Anderson Cancer Center experience.
Authors: S. P. Lynch, T. T. Vu, A. M. Kamat, H. B. Grossman, R. E. Millikan, C. P. Dinney, A. O. Siefker-Radtke
Journal: Journal of Clinical Oncology (2010)

4566 Background: Recently, data from a small phase II clinical trial suggested a role for neoadjuvant chemotherapy in small cell urothelial carcinoma (SCUC). However, the numbers of patients treated with this strategy to date remains quite limited. We now report results from 96 patients with SCUC seen at MDACC who underwent a cystectomy with or without neoadjuvant chemotherapy. Methods: We reviewed records from 175 patients with SCUC who were seen at the MDACC between 1985 and 2009. Charts were reviewed for clinical and pathological stage, surgical setting, and survival times. Results: Of the 96 patients who underwent a cystectomy for surgically resectable (<=T4aN0M0) SCUC, 48 received neoadjuvant chemotherapy. Neoadjuvant chemotherapy was associated with a significant improvement in overall survival (OS) from resection (median OS 83 mo.) as compared to the group treated with initial surgery (median OS 15.3 mo., p = 0.000001), with a 5-year disease- specific survival (DSS) of 63% and 14%, respectively. The addition of adjuvant chemotherapy in 21 patients did not improve survival as compared to those treated with cystectomy alone. Pathologic down-staging to <=pT2N0M0 with neoadjuvant chemotherapy was associated with an improved outcome (5-year DSS 80%) as compared to those who had >=pT3, N+, or M+ disease at cystectomy (median DSS 13 mo, p = 0.00001). The presence of metastatic disease continues to have a poor prognosis with a median OS of 12.8 months. Conclusions: Neoadjuvant chemotherapy is associated with improved outcomes as compared to those patients treated with initial surgery. The persistence of Stage 3 or greater disease despite neoadjuvant chemotherapy continues to have a poor prognosis. Our current strategy is to offer 4 cycles of neoadjuvant chemotherapy with a small cell chemotherapy regimen to patients with surgically resectable SCUC. No significant financial relationships to disclose.
Increased Nucleosomal DNA Fragmentation in Leukocytes of Thalassemia Patients.
Authors: Patrick B Walter, John B Porter, Patricia Evans, Janet Kwiatkowski, Ellis J. Neufeld, Thomas D. Coates, Patricia Giardina, Robert jW Grady, Elliott Vichinsky, Nancy F. Olivieri, Felicia Trachtenberg, Daniele Alberti, Ellen Fung, Bruce Ames, Annie Lui, Paul Harmatz
Journal: Blood (2008)
Study of survival in non metastatic surgical colon cancer
Authors: E. Saigí, E. Musulén, Y. García-García, J. Bombardó, M. Nogué, M. A. Seguí, L. Fernández-Morales, S. Martinez-Peralta, M. Rey, C. Pericay
Journal: Journal of Clinical Oncology (2004)

3750 Background: Colon cancer is the second neoplasm in men and women. Its prognostic depends on TNM staging at diagnosis. The treatment seems to improve the survival. The aim of this study is to analyze our series of surgical colon cancer from 1996 to 2001. Methods: We analyzed 422 surgical colon cancer. 70 patients were metastatic at the time of diagnosis or behind surgery (5 months). The remainder 352 patients without metastases were analyzed. The prognosis factors were: age at diagnosis, gender, locations in the large bowel, kind of surgery, pT, pN, stage, use of chemotherapy, disease free survival (DFS) and overall survival (OS). Results: The 352 non metastatic surgical colon cancer presented a mean age at diagnosis of 70,22 years (24 to 101). The ratio male/female was 197/155. The location in the bowel was: right 149 cases and left 203 cases. pT: pTis 6, pT114, pT2 43, pT3 244, pT4 41. pN: pN0 + pNX 229, pN1 70, pN2 52. 145 patients received adjuvant chemotherapy. Stage: I:49; II:171; III:122.pT: DFS was pT1=100%, pT2=93%, pT3=73%, pT4=51,2%. OS was pT1=71,4%, pT2=83,7%, pT3=66%, pT4=48,8%.pN: DFS was pN0=83,4%, pN1=64,3%,pN2=50%. OS was pN0=70,3%, pN1=61,4%, pN2=55,8%. Stage: OS was I=80%, II=68%, III=59%. Conclusions: The main prognostic factor for survival in colon cancer was the staging at diagnosis. Patients with pT4 or pN2 should received aggressive treatments for the high risk of metastasis. No significant financial relationships to disclose.
Monitoring Response to Imatinib by Fluorescence In Situ Hybridization (FISH) and Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) in Chronic Myeloid Leukemia (CML) Patients in Chronic Phase. Experience of Argentina and Uruguay.
Authors: Isabel A. Giere, Carolina Pavlovsky, MaVirginia Lombardi, Pedro Negri, Beatriz Moiraghi, Juan Garcia, Miguel A. Pavlovsky, Jorge Milone, Raquel Bengio, Reinaldo Campestri, Valentin Labanca, Nora Mur, MaFernanda Garcia Reinoso, Veronica Chiaramello, German Bono, Sergio Pintos, Rosario Uriarte, Alicia Magarinos, Lem Martinez, Claudia Corrado, Isolda Fernandez, Santiago Pavlovsky
Journal: Blood (2006)
Improved Clinical Outcomes in Chronic Lymphocytic Leukemia Patients with 17p Deletion (CLL 17p-) Who Are Able to Proceed with a Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) Following an Initial Consultation with the Transplant Service: A Single Centre Experience
Authors: LM Poon, Patricia S Fox, Barry I. Samuels, Susan O'Brien, Alessandra Ferrajoli, Michael J. Keating, Elias J. Jabbour, Yvonne Hsu, Lynne V. Abruzzo, Richard E. Champlin, Roland Bassett, Issa F. Khouri
Journal: Blood (2012)
Fit with good fat? The role of n-3 polyunsaturated fatty acids on exercise performance
Authors: Mariasole Da Boit, Angus M. Hunter, Stuart R. Gray
Journal: Metabolism (2016)

N-3 PUFA (n-3) polyunsaturated fatty acids (PUFA) are a family of fatty acids mainly found in oily fish and fish oil supplements. The effects of n-3 PUFA on health are mainly derived from its anti-inflammatory proprieties and its influence on immune function. Lately an increased interest in n-3 PUFA supplementation has reached the world of sport nutrition, where the majority of athletes rely on nutrition strategies to improve their training and performance. A vast amount of attention is paid in increasing metabolic capacity, delaying the onset of fatigue, and improving muscle hypertrophy and neuromuscular function. Nutritional strategies are also frequently considered for enhancing recovery, improving immune function and decreasing oxidative stress. The current review of the literature shows that data regarding the effects of n-3PUFA supplementation are conflicting and we conclude that there is, therefore, not enough evidence supporting a beneficial role on the aforementioned aspects of exercise performance.
Abstract B06: Characterizing the effects of hypoxia and hydrostatic pressure on the expression of immunotherapeutic targets in prostate cancer cell lines and donor immune cells in culture
Authors: Bruce A. Adams, James Lim, Tianna Chow, Susan Bernstein, Charles J. Ryan
Journal: Cancer Research (2016)

Abstract Introduction: Cancer immunotherapy has changed the paradigm of cancer treatment by harnessing the immune system to identify and eradicate tumors leading to significant improvements in the objective response and long term survival of patients. However, more than 50% of patients do not respond to the most advanced immunotherapeutics in clinical trials, suggesting that further research is needed to understand the mechanism of action and resistance to immune-modulating agents in patients. The current hypothesis is that the tumor microenvironment can modulate the reprogramming of stromal cells caused by chronic inflammation, leading to a suppressed immune system that is highlighted by T-cell exhaustion and anergy. Hypoxia and high interstitial fluid pressure within tumors are elements that may contribute to gene and protein expression changes in stromal, immune and tumor cells in the microenvironment to inhibit immune function and promote cancer proliferation and metastasis. Methods: We have developed a novel primary cell culture bioreactor to modulate both oxygen level (0.1% to 19%) and hydrostatic pressure levels (26 to 260 mmHg / 0.5 psig to 5 psig) to study the effects on gene and protein expression profiles of prostate cancer cell lines and peripheral blood mononuclear cells (PBMCs) derived from donors. We performed high-resolution immunofluorescence imaging and western blot protein expression analysis of primary immuno-therapy targets CTLA-4, PD-1, and PD-L1. In addition, whole transcriptome sequencing was performed on cells across a range of physiologically-relevant culturing conditions to mimic various tumor microenvironments found within the body. Conclusions: We report that prostate cancer cell lines and PBMCs differentially express immunotherapeutic targets when cultured at physiologically relevant tumor microenvironment conditions, resulting in reduced expression of key targets. Analysis of mRNA-seq data revealed alterations in gene expression profiles of immunotherapeutic and drug-target pathways involving CTLA-4 and AR signaling. In contrast, we observed increased CD47 and CD44 expression at low oxygen and high pressure culturing conditions in cancer cell lines and PBMCs. These data highlight the importance of using physiologically relevant microenvironment conditions that include hypoxia and pressure to identify biomarkers and drug target candidates. Citation Format: Bruce A. Adams, James Lim, Tianna Chow, Susan Bernstein, Charles J. Ryan. Characterizing the effects of hypoxia and hydrostatic pressure on the expression of immunotherapeutic targets in prostate cancer cell lines and donor immune cells in culture. [abstract]. In: Proceedings of the AACR Special Conference: Function of Tumor Microenvironment in Cancer Progression; 2016 Jan 7–10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2016;76(15 Suppl):Abstract nr B06.
Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.
Authors: Edward B. Garon, Roy S. Herbst, Dong-Wan Kim, Enriqueta Felip, Jose Luis Perez-Gracia, Ji-Youn Han, Julian R. Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J. Fidler, Matthew A. Gubens, Gilberto Castro, Marcelo Garrido, Yue Shentu, Ellie Im, Gregory M. Lubiniecki, Paul Baas
Journal: Journal of Clinical Oncology (2016)

9024 Background: KEYNOTE-010 (NCT01905657) showed that the anti–PD-1 antibody pembrolizumab (pembro; MK-3475) at doses of 2 and 10 mg/kg Q3W provided superior OS over docetaxel in patients (pts) with previously treated, PD-L1–positive advanced NSCLC: HR 0.71, P = 0.0008 for 2 mg/kg and 0.61, P < 0.0001 for 10 mg/kg. Efficacy was greatest in the co-primary, PD-L1 TPS ≥ 50% population: HR 0.54, P = 0.0002 and 0.50, P < 0.0001. In a post hoc analysis, we assessed efficacy in pts with TPS 1%-49% enrolled in KEYNOTE-010. Methods: Key eligibility criteria were disease progression after ≥ 2 cycles of platinum-doublet chemotherapy, an appropriate TKI for EGFR or ALK aberrations, and PD-L1 TPS ≥ 1% assessed by IHC using the 22C3 antibody. 1034 pts were randomized to pembro 2 or 10 mg/kg Q3W or docetaxel 75 mg/m2 Q3W for 24 mo or until disease progression, intolerable toxicity, or other reason. PD-L1 TPS (1%-49% vs ≥ 50%) was a randomization stratification factor. Response was assessed per RECIST v1.1 by central review every 9 wk. Survival was assessed every 2 mo. Both OS and PFS were primary end points. ORR and duration of response (DOR) were secondary end points. Results: 591 (57.2%) pts had TPS 1%-49%. Pembro improved OS in the 1%-49% strata: HR 0.79 for pembro 2 mg/kg (median 9.4 mo) and 0.71 for pembro 10 mg/kg (median 10.8 mo) vs docetaxel (median 8.6 mo) (Table), with no apparent difference between pembro doses (HR 1.15; 95% CI 0.88-1.52). PFS and ORR were similar in the pembro and docetaxel arms, whereas DOR was longer with pembro (Table). Conclusions: Pembro prolongs OS over docetaxel in pts with a PD-L1 TPS 1%-49%. This suggests that the OS benefit reported in the total population of KEYNOTE-010 was not driven solely by pts with TPS ≥ 50%. The OS benefit in the TPS 1%-49% stratum coupled with the lack of a PFS and ORR benefit suggests these measures may under-represent the benefit of pembro. Clinical trial information: NCT01905657. Pembro 2 mg/kg N = 205 Pembro 10 mg/kg N = 195 Docetaxel N = 191 OS, median, mo 9.4 10.8 8.6 HR (95% CI) 0.79 (0.61-1.04) 0.71 (0.53-0.94) — PFS, median, mo 3.1 2.3 3.9 HR (95% CI) 1.07 (0.85-1.34) 0.99 (0.78-1.25) — ORR, % (95% CI) 9.8 (6.1-14.7) 10.3 (6.4-15.4) 10.5 (6.5-15.7) DOR, median (range), mo 46 (9+ to 87+) 45 (13+ to 74+) 26 (6+ to 31)
Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL).
Authors: Ephraim P. Hochberg, Nicole Birrer, Christiana E. Toomey, Jeffrey A. Barnes, Alfred Ian Lee, Ann LaCasce, Jeremy S. Abramson
Journal: Blood (2009)
First Experience With SPECT/CT Using a 99mTc-Labeled Inhibitor for Prostate-Specific Membrane Antigen in Patients With Biochemical Recurrence of Prostate Cancer
Authors: Julia Reinfelder, Torsten Kuwert, Michael Beck, James C. Sanders, Philipp Ritt, Christian Schmidkonz, Peter Hennig, Olaf Prante, Michael Uder, Bernd Wullich, Peter Goebell
Journal: Clinical Nuclear Medicine (2016)

Prostate-specific membrane antigen (PSMA) is overexpressed in most prostate cancers (PCs). Here, we report our first experience using the Tc-labeled PSMA inhibitor MIP-1404 (Progenics Pharmaceuticals, Inc, Tarrytown, NY) in 60 patients with biochemically recurrent PC.Whole-body planar scintigraphy and SPECT/CT of the lower abdominal pelvic region of 60 patients with biochemical relapse of PC were analyzed retrospectively. In these subjects, an average dose of 733.1 ± 49.5 MBq (19.8 ± 1.3 mCi) Tc-labeled MIP-1404 was injected 4 to 5 hours prior to imaging. In addition to visual evaluation, SUVmax were determined in the tumor lesions using a previously developed protocol for quantitative SPECT/CT.In 42 of 60 patients, Tc-MIP-1404-positive lesions could be detected (70%; 95% confidence interval [CI], 0.58-0.82). Twenty patients had Tc-MIP-1404-positive lymph nodes suggestive of metastasis, 14 patients had pathological uptake in the prostate region indicative of local recurrence, and for another 19 patients, there was tracer accumulation in the skeleton (n = 18) or lungs (n = 1). Detection rate was 91.4% (95% CI, 0.82-1) at prostate-specific antigen levels greater than 2 ng/mL and 40.0% (95% CI, 0.21-0.59) at lower prostate-specific antigen values (P < 0.01). Of the 60 patients, in total, 82 positive lesions were analyzed quantitatively. Average SUVmax of the lesions was 16.3 ± 21.6 with a range of 1.7 to 142.9.Tc-labeled PSMA inhibitor MIP-1404 is a promising SPECT tracer for detection of locally recurrent or metastatic prostate cancer.
AAV8-Factor IX Hepatic Gene Transfer with Transient Immunosuppression Is Safe but Is Abrogated by Low Titers of Neutralizing Antibody in Rhesus Macaques.
Authors: Haiyan Jiang, Susannah Patarroyo-White, Tongyao Liu, Bin Yang, Dea Nagy, Lin He, Ciaran D. Scallan, Jurg Sommer, Shangzhen Zhou, Linda B. Couto, Katherine A. High, Glenn F. Pierce
Journal: Blood (2005)
BACOP/FR combination chemotherapy as front-line treatment of follicular lymphoma. A phase II study of the Gruppo Italiano Studio Linfomi (GISL)
Authors: S. Luminari, M. Lombardo, C. Mammi, M. Bellei, F. Merli, C. Stelitano, A. Lazzaro, R. Marasca, M. Brugiatelli, M. Federico
Journal: Journal of Clinical Oncology (2006)

7571 Background: Doxorubicin, fludarabine and rituximab are all considered active drugs in the treatment of follicular lymphoma (FL). Howevere, the best induction regimen is still matter of debate. In 2003 the GISL started a phase II trial to assess efficacy and tolerability of a combination of bleomycin, adriamycin, ciclophosphamide, vincristine and prednisone (BACOP) followed by fludarabine and rituximab (FR). Methods: To be included in the study pts should have: histologically confirmed diagnosis of FL, stage II-IV disease, age 18–70, active disease. Pts were assessed for t(14:18) by PCR on bone marrow at diagnosis and at time of response assessment. Treatment consisted in three courses of BACOP followed by 4 courses of FR for pts in partial remission (PR) or complete remission with persistent t(14:18) positivity (CRM+). Pts achieving molecular complete remission (CRM-) stopped therapy after BACOP. The main endpoints of the study were overall response rate (CR+PR) (ORR) and failure free survival (FFS). A final accrual of 60 assessable pts was planned, however a faster accrual than expected allowed to enrol 91 pts between May 2003 and Dec 2005. Results: At time of present analysis 61 pts were valuable for final response: Median age was 56 yrs (25–70), male gender 56%, 18% with systemic symptoms, 88% in stage III-IV disease, 13% had elevated LDH and 21% bulky disease. Molecular marker was present in 30 out of 57 pts. 19 pts achieved a CR after three courses of BACOP; four of them, being in CRM- stopped therapy. 28 pts achieved CR with four additional courses of FR. At the end of treatment CR and ORR were 77% and 90% respectively; relatively to pts with molecular marker at diagnosis CRM- was 60%. Toxicity data are available for 57 patients: grade III/IV anemia and neutropenia were observed in two (3%) and 18 (32%) cases respectively; severe infections occurred in two cases, both bacterial pneumonia. After a median follow-up of 17 months (0.5–31) 12 events were observed: Major toxicity, four; non responders, two; relapse, six. Conclusions: BACOP/FR is a feasible and safe regimen for the treatment of patients with FL with promising efficacy. More mature follow-up is required to confirm these preliminary results. No significant financial relationships to disclose.
Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Authors: Ludger Schöls
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Immunization with Live-Attenuated Listeria Encoding CMV Antigen Induces Extensive Expansion of CMV-Specific CD8+ T-Cells Following HSCT: An Alternative to Adoptive Antiviral Immunotherapy.
Authors: John D. Roback, Levan J. Lezhava, Elisabeth Hesse, Christopher D. Hillyer, William Luckett, Thomas W. Dubensky, Martin Giedlin
Journal: Blood (2004)
Feasibility of the AMLprofiler™ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach
Authors: Josep F Nomdedeu, Eulalia Puigdecanet, Elena Bussaglia, Juan J Hernandez, Maite Carricondo, Camino Estivill, Josep M Marti-Tutusaus, Mar Tormo, Lurdes Zamora, Josep-Maria Ribera, Lara Nonell, Anna Aventin, Francesc Sole, Salut Brunet, Jorge Sierra
Journal: Blood (2012)
Unanswered Questions Concerning Locoregional Irradiation in Breast Cancer—Reply
Authors: Jay R. Harris
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012
Authors: Kevin D. Shield, Jacques Ferlay, Ahmedin Jemal, Rengaswamy Sankaranarayanan, Anil K. Chaturvedi, Freddie Bray, Isabelle Soerjomataram
Journal: CA A Cancer Journal for Clinicians (2016)

ABSTRACT By using data from the International Agency for Research on Cancer publication Cancer Incidence in 5 Continents and GLOBOCAN, this report provides the first consolidated global estimation of the subsite distribution of new cases of lip, oral cavity, and pharyngeal cancers by country, sex, and age for the year 2012. Major geographically based, sex‐based, and age‐based variations in the incidence of lip, oral cavity, and pharyngeal cancers by subsite were observed. Lip cancers were highly frequent in Australia (associated with solar radiation) and in central and eastern Europe (associated with tobacco smoking). Cancers of the oral cavity and hypopharynx were highly common in south‐central Asia, especially in India (associated with smokeless tobacco, bidi, and betel‐quid use). Rates of oropharyngeal cancers were elevated in northern America and Europe, notably in Hungary, Slovakia, Germany, and France and were associated with alcohol use, tobacco smoking, and human papillomavirus infection. Nasopharyngeal cancers were most common in northern Africa and eastern/southeast Asia, indicative of genetic susceptibility combined with Epstein‐Barr virus infection and early life carcinogenic exposures (nitrosamines and salted foods). The global incidence of lip, oral cavity, and pharyngeal cancers of 529,500, corresponding to 3.8% of all cancer cases, is predicted to rise by 62% to 856,000 cases by 2035 because of changes in demographics. Given the rising incidence of lip, oral cavity, and pharyngeal cancers and the variations in incidence by subsites across world regions and countries, there is a need for local, tailored approaches to prevention, screening, and treatment interventions that will optimally reduce the lip, oral cavity, and pharyngeal cancer burden in future decades. CA Cancer J Clin 2017;67:51–64. © 2016 American Cancer Society .
High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.
Authors: Edwin P. Alyea, Shuli Li, Haesook Kim, Vincent T. Ho, Corey Cutler, Stephanie J. Lee, John Gribben, Richard M. Stone, Daniel J. DeAngelo, Jerome Ritz, Joseph H. Antin, Robert J. Soiffer
Journal: Blood (2004)
RGS1 and RGS13 Regulate SDF-1-Mediated Responses and Homing in Human Cord Blood CD34+ Hematopoietic Stem/Progenitor Cells
Authors: Yorky Tsin Sik Wong, Kam Tong Leung, Karen Li, Kathy Yuen Yee Chan, Xiao-Bing Zhang, Tak Yeung Leung, Kam Sze Tsang, Ting Fan Leung, Pak Cheung Ng, Chi Kong Li
Journal: Blood (2015)